The management of hepatitis, a global health concern, has seen significant advancements over the past few years. This article aims to provide healthcare professionals with a comprehensive update on the recent developments in the field.
Newer antiviral therapies have revolutionized the treatment of hepatitis C (HCV). Direct-acting antivirals (DAAs) have demonstrated high cure rates, excellent tolerability, and a short treatment duration. The pan-genotypic regimens like Glecaprevir/Pibrentasvir have simplified HCV management, offering a one-size-fits-all approach.
For hepatitis B (HBV), the focus remains on prevention through vaccination. The recent development of a therapeutic vaccine, currently in clinical trials, aims to stimulate the immune system to fight against chronic HBV infection, offering a promising approach for functional cure.
Non-invasive assessment tools for liver fibrosis, such as transient elastography (FibroScan), have become increasingly popular. These tools provide a safer and more comfortable alternative to liver biopsy, facilitating regular monitoring and early detection of disease progression.
For hepatitis D (HDV), a novel entry inhibitor, Bulevirtide, has shown efficacy in reducing HDV RNA levels. In hepatitis E (HEV), Ribavirin remains the treatment of choice, with Sofosbuvir showing potential as an alternative therapy.
These advancements underscore the rapid evolution in hepatitis management. While the advent of DAAs has transformed HCV treatment, novel approaches like therapeutic vaccines for HBV and non-invasive tools for fibrosis assessment hold significant potential. Further research is required to address unmet needs in HDV and HEV management. As healthcare professionals, staying abreast of these developments is crucial to provide optimal patient care.
1.
Talquetamab Combos Show Survival Benefit in r/r Myeloma
2.
From sweetener to cancer fighter? Fermented stevia shows promise in pancreatic cancer study
3.
Year in Review: Non-Small Cell Lung Cancer
4.
FINAL USPSTF RECOMMENDATIONS ON ANXIETY, DEPRESSION, AND SUIICIDAL RISK.
5.
Liposomal Chemo Combination No Better Than Standard Induction in Pediatric AML
1.
Targeted Therapies for Breast Cancer: What’s New?
2.
Ultrasound: A Promising Tool in the Fight Against Malignant Breast Cancer
3.
Adjuvant Atezolizumab in TNBC: What Recent Trials Reveal About Its Role
4.
Revolutionizing Cancer Care: The Transformative Role of AI and Data Science in Oncology
5.
Sorafenib: Understanding the science behind a powerful cancer drug
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion
2.
ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis
3.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III
4.
Common Cancer Myths Debunked
5.
Dissecting Molecular differences between EGFR Exon 19 deletion and Exon 21 L858R Mutations
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation